A Phase 2 interventional study of Bis-Chloroethyl-Nitroso-Urea (BCNU) withTemozolomide in Oligodendroglioma; Oligoastrocytoma, sponsored by Assistance Publique Hopitaux De Marseille. Completed at 1 site in France. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-07.
Sponsored by Assistance Publique Hopitaux De Marseille · Phase 2, Interventional, and Treatment
The first-line treatment of anaplastic oligodendrogliomas, radiotherapy exclusive or combined with PCV, will be defined by the pending results of phase III of the EORTC.
If the phase II study proposed here achieves its objective, it may help define a new treatment regimen that will be compared to the standard arm from phase III of the EORTC.
In addition, this study, by prospectively testing the predictive value of 1p and 19q deletions and of REGF amplification, may allow characterization of patients using these markers. If validated, this characterization can constitute a key element in any therapeutic evaluation (patient stratification), and potentially a major tool for medical decision support in these tumors.
218 studies on the registry are indexed under Oligodendroglioma; 31 are open to participants now.
This study's enrollment of 53 is above the median of 32 across 180 interventional studies indexed under Oligodendroglioma.
Browse Oligodendroglioma studies →Assistance Publique Hopitaux De Marseille is the lead sponsor of 686 studies on the registry; 148 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Administration of 6 cycles of chemotherapy
Drug: Bis-Chloroethyl-Nitroso-Urea (BCNU) withTemozolomide
Chemotherapy (BCNU) will be delivered at Day 1. between day 1 and day 5, temolozomide will be administered . One cycle is planned every 6 weeks until 6 cycles.
Objective response rate of the BCNU-TMZ combination administered before radiotherapy
In oligodendrogliomas and anaplasic oligoastrocytomas as the first line of treatment
Time frame: At the end of Cycle 2 (each cycle is 28 days)
Objective response rate of the BCNU-TMZ combination administered before radiotherapy
In oligodendrogliomas and anaplasic oligoastrocytomas as the first line of treatment
Time frame: At the end of Cycle 4 (each cycle is 28 days)
Objective response rate of the BCNU-TMZ combination administered before radiotherapy
In oligodendrogliomas and anaplasic oligoastrocytomas as the first line of treatment
Time frame: At the end of Cycle 6 (each cycle is 28 days)
Objective response rate of the BCNU-TMZ combination administered before radiotherapy
In oligodendrogliomas and anaplasic oligoastrocytomas as the first line of treatment
Time frame: 1 month after radiotherapy
Plan to share: No
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique Hopitaux De Marseille